Abstract：ObjectiveTo investigate the effect of Thalidomide combined with conventional chemotherapy treating acute myeloid leukemia(AML).MethodsSixty-three newly diagnosed AML in our hospital from January to December 2013 were selected.They were divided into Thalidomide combined with routine chemotherapy group(combined group,35 cases)and routine chemotherapy group(control group,28 cases).All patients were treated with DA chemotherapy regimen for 4 courses (7 d for a course of treatment),while the combined group was given thalidomide for 4 months.The changes of VEGF, VEGFR,bFGF,MVD and the long-term survival status in the two groups were recorded and compared,the efficacy and incidence of adverse reactions were analyzed.ResultsThe effective rate in the combined group was 88.57%,and it was significantly higher than 60.71%in the control group(P<0.05).After treatment,the level of VEGF,VEGFR,bFGF and MVD in the two groups were significantly lower than those before treatment(P<0.05).And the level of VEGF,VEGFR and MVD in the combined group were significantly lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05)besides digestive system symptoms,which in the combined group(65.71%)was significantly higher than that in the control group(17.86%).ConclusionThe therapy of Thalidomide combined with conventional chemotherapy can effectively inhibit the expression of VEGF and VEGFR and the production of bone marrow microvessels in patients with AML.But it had no significant effect on the patients′long-term survival rate.
Popat R，Brown SR，Flanagan L，et al.Bortezomib，thalidomide，dexamethasone，and panobinostat for patients with relapsed multiple myeloma（MUK-six）：a multicentre，open-label，phase 1/2 trial[J].Lancet Haematol，2016，3（12）：e572-e580.
[6]
Luo J，Gagne JJ，Landon J，et al.Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America：a population-based cohort study[J].Eur J Cancer，2017，70：22-33.
Reikvam H，Nepstad I，Sulen A，et al.Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors[J].Expert Opin Investig Drugs，2013，22（5）：551-563.
[13]
El-Aarag B，Kasai T，Masuda J，et al.Anticancer effects of novel thalidomide analogs in A549 cells through inhibition of vascular endothelial growth factor and matrix metalloproteinase-2[J].Biomed Pharmacother，2017，85：549-555.
[14]
Lopesaguiar L，Delamain MT，Brito ABC，et al.VEGF，VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients in the thalidomide era[J].Clin Lymphoma Myeloma Leuk，2016，16：S70-S71.
Buchner T，Berdel WE，Haferlach C，et al.Age-related risk profile and chemotherapy dose response in acute myeloid leukemia：a study by the German Acute Myeloid Leukemia Cooperative Group[J].J Clin Oncol，2009，27（1）：61-69.
京公网安备 11010502046607号